Mouse anti Cytokeratin 7 / Keratin K7
| Code | Size | Price |
|---|
| MUB0316P | 0.1 mg | £326.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG1
Antibody Clonality: Monoclonal
Antibody Clone: OVTL12/30
Regulatory Status: RUO
Target Species: Human
Application: Flow Cytometry
Storage:
Store at 4°C or in small aliquots at -20°C.
Documents
Further Information
Applications Description:
OVTL12/30 is effective on frozen tissue after fixation in methanol. It is particularly effective on paraffin-embedded tissue, for which pretreatment with e.g. 0.1% pronase / 0.1% trypsine in PBS or 0.5% pepsine in 0.01N HCl or microwave pretreatment is required. In addition, OVTL 12/30 is suitable for immunocytochemistry, immunoblotting and flow cytometry. Optimal antibody dilution should be determined by titration; recommended range is 1:100 ? 1:200 for flow cytometry, and for immunohistochemistry with avidin-biotinylated Horseradish peroxidase complex (ABC) as detection reagent, and 1:100 ? 1:1000 for immunoblotting applications.
Background:
Cytokeratins are a subfamily of intermediate filament proteins and are characterized by a remarkable biochemical diversity, represented in Human epithelial tissues by at least 20 different polypeptides. They range in molecular weight between 40 kDa and 68 kDa and isoelectric pH between 4.9 ? 7.8. The individual Human Cytokeratins are numbered 1 to 20. The various epithelia in the Human body usually express Cytokeratins which are not only characteristic of the type of epithelium, but also related to the degree of maturation or differentiation within an epithelium. Cytokeratin subtype expression patterns are used in the distinction of different types of epithelial malignancies. The Cytokeratin antibodies are not only of assistance in the differential diagnosis of tumors using immunohistochemistry on tissue sections, but are also a useful tool in cytopathology and flow cytometric assays.
Caution:
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.
This product contains sodium azide. To prevent formation of toxic vapors, do not mix with strong acidic solutions. To prevent formation of potentially explosive metallic azides in metal plumbing, always wash into drain with copious quantities of water.
This datasheet is as accurate as reasonably achievable, but Nordic-MUbio accepts no liability for any inaccuracies or omissions in this information.
This product contains sodium azide. To prevent formation of toxic vapors, do not mix with strong acidic solutions. To prevent formation of potentially explosive metallic azides in metal plumbing, always wash into drain with copious quantities of water.
This datasheet is as accurate as reasonably achievable, but Nordic-MUbio accepts no liability for any inaccuracies or omissions in this information.
Field of Interest:
Cancer|Cytoskeleton|Stem cell research
Formulation:
Each vial contains 100 ul 1 mg/ml purified monoclonal antibody in PBS containing 0.09% sodium azide.
Product:
Each vial contains 100 ul 1 mg/ml purified monoclonal antibody in PBS containing 0.09% sodium azide.
Source:
OVTL12/30 is a Mouse monoclonal IgG1/? antibody derived by fusion of SP2/0-Ag14 Mouse myeloma cells with spleen cells from a BALB/c Mouse immunized with a cytoskeletal preparation of OTN-11 ovarian carcinoma cell line.
Specificity:
OVTL12/30 reacts exlcusively with Cytokeratin 7 which is present in specific glandular-type epithelia and most carcinomas derived thereof.
UniProt:
P08729
References
1. Ramaekers, F., van Niekerk, C., Poels, L., Schaafsma, E., Huijsmans, A., Robben, H., Schaart, G., and Vooijs, P. (1990). Use of monoclonal antibodies to Keratin 7 in the differential diagnosis of adenocarcinomas, Am J Pathol 136, 641-55.
2. van Niekerk, C. C., Jap, P. H., Ramaekers, F. C., van de Molengraft, F., and Poels, L. G. (1991). Immunohistochemical demonstration of Keratin 7 in routinely fixed paraffin-embedded Human tissues, J Pathol 165, 145-52.
3. van Niekerk, C. C., Boerman, O. C., Ramaekers, F. C., and Poels, L. G. (1991). Marker profile of different phases in the transition of normal Human ovarian epithelium to ovarian carcinomas, Am J Pathol 138, 455-63.
4. van de Molengraft, F. J., van Niekerk, C. C., Jap, P. H., and Poels, L. G. (1993). OV-TL 12/30 (Keratin 7 antibody) is a marker of glandular differentiation in lung cancer, Histopathology 22, 35-8.
5. van Niekerk, C. C., Vooijs, P., Casparie-van Velsen, I. J., and Poels, L. G. (1997). Differentiation margins of ovarian tumor pathology: first incidences of epithelial ovarian tumors monitored by marker antibodies, Cancer Detect Prev 21, 247-57.
6. Torenbeek, R., Lagendijk, J. H., Van Diest, P. J., Bril, H., van de Molengraft, F. J., and Meijer, C. J. (1998). Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma, Histopathology 32, 20-7.
2. van Niekerk, C. C., Jap, P. H., Ramaekers, F. C., van de Molengraft, F., and Poels, L. G. (1991). Immunohistochemical demonstration of Keratin 7 in routinely fixed paraffin-embedded Human tissues, J Pathol 165, 145-52.
3. van Niekerk, C. C., Boerman, O. C., Ramaekers, F. C., and Poels, L. G. (1991). Marker profile of different phases in the transition of normal Human ovarian epithelium to ovarian carcinomas, Am J Pathol 138, 455-63.
4. van de Molengraft, F. J., van Niekerk, C. C., Jap, P. H., and Poels, L. G. (1993). OV-TL 12/30 (Keratin 7 antibody) is a marker of glandular differentiation in lung cancer, Histopathology 22, 35-8.
5. van Niekerk, C. C., Vooijs, P., Casparie-van Velsen, I. J., and Poels, L. G. (1997). Differentiation margins of ovarian tumor pathology: first incidences of epithelial ovarian tumors monitored by marker antibodies, Cancer Detect Prev 21, 247-57.
6. Torenbeek, R., Lagendijk, J. H., Van Diest, P. J., Bril, H., van de Molengraft, F. J., and Meijer, C. J. (1998). Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma, Histopathology 32, 20-7.